Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Pleural Diseases 2Pancreatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Non-Muscle Invasive Bladder Neoplasms 1Mesothelioma, Malignant 1Glioma 1Glioblastoma 1Epitheliod Malignant Pleural Mesothelioma 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Basal Cell 1

Interventions

pembrolizumab 44Gemcitabine 23Nivolumab 21enfortumab vedotin 20Cisplatin 17avelumab 16Magnetic Resonance Spectroscopy 16Carboplatin 14atezolizumab 13Specimen Handling 12Docetaxel 11sacituzumab govitecan 9Paclitaxel 8Ipilimumab 8durvalumab 6Mitomycin 5Fluorodeoxyglucose F18 5cabozantinib 4Taxes 4toripalimab 3pemigatinib 3erdafitinib 3X-Rays 3Radiosurgery 3Platinum 3Pemetrexed 3Immunoglobulin G 3CTLA-4 Antigen 3Biopsy 3ALT-803 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × 1-phenyl-3,3-dimethyltriazene × 1 year × Clear all
NCT03945162 2025-11-24

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

TheralaseĀ® Technologies Inc.

Phase 2 Recruiting
90 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚔